MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α
© Chen et al. 2016
Received: 21 July 2015
Accepted: 27 January 2016
Published: 2 February 2016
Endometrial carcinoma (EC) is one of the most lethal gynecologic cancers. Patients frequently have regional or distant metastasis at diagnosis. MicroRNAs are small non-coding RNAs that participate in numerous biological processes. Recent studies have demonstrated that miR-505 is associated with several types of cancer; however, the expression and function of miR-505 have not been investigated in EC.
miR-505 expression in normal endometrial tissue, endometrial carcinomas were quantified by Quantitative reverse transcription PCR. The endometrial carcinoma cell lines HEC-1B and Ishikawa were each transfected with miR-505 or scrambled mimics, after which cell phenotype and expression of relevant molecules were assayed. Dual-luciferase reporter assay and a xenograft mouse model were used to examine miR-505 and its target gene TGF-α.
RT-PCR results demonstrated that miR-505 was significantly downregulated in human EC tissues compared to normal endometrial tissues. Besides, miR-505 expression was negatively associated with FIGO stage (stage I-II vs. III-IV), and lymph node metastasis (negative vs. positive). In vitro, overexpression of miR-505 significantly suppressed EC cell proliferation, increased apoptosis and reduced migratory and invasive activity. A miR-505 binding site was identified in the 3′ untranslated region of TGF-α mRNA (TGFA) using miRNA target-detecting software; a dual luciferase reporter assay confirmed that miR-505 directly targets and regulates TGFA. RT-PCR and Western-blotting results indicated that overexpressing miR-505 reduced the expression of TGF-α and the TGF-α-regulated proteins MMP2, MMP9, CDK2, while induced Bax and cleaved-PARP expression in EC cells. In vivo, overexpression of miR-505 reduced the tumorigenicity and inhibited the growth of xenograft tumors in a mouse model of EC.
Taken together, this study demonstrates that miR-505 acts as tumor suppressor in EC by regulating TGF-α.
KeywordsMiR-505 TGF-α Endometrial carcinoma Tumorigenesis Progression
Endometrial carcinoma (EC) is one of the three most common types of gynecologic cancer and its global incidence has increased in recent years . It is known that endometrial carcinoma is divided into estrogen dependent (type I) and non-estrogen dependent (type II) [2, 3]. The pathogenesis of type I endometrial carcinoma is that under the long-term effects of estrogen, but without the antagonistic effects of progesterone, the endometrium progressively increases in thickness and therefore becomes more susceptible to becoming cancerous [4, 5]. Generally, FIGO stage I (2009) endometrial carcinoma is considered to have a good prognosis with a 5-year survival rate of up to 96 % . Unfortunately, as multiple factors affect recurrence, including surgical stage, differentiation and lymph node metastasis, effective therapies for patients with advanced-stage EC or disease recurrence are still lacking , the 5-year OS rate of the FIGO stages II–IV was 76.0 % . The identification and further elucidation of the molecular mechanisms responsible for EC tumorigenesis and progression may have a major impact on the health of females.
MicroRNAs are a group of endogenous, small, 18–25 base-long non-coding RNAs that influence multiple biological processes including proliferation, apoptosis, senescence, differentiation and development by post-transcriptionally repressing gene expression or inducing mRNA degradation via binding to the 3′ untranslated regions (UTR) of specific target genes [9–11]. MicroRNAs can target approximately 20–30 % of genes. A single microRNA can target at least 200 genes, and a single gene can be regulated by many RNAs [12–14]. A large body of research has demonstrated that dysregulation of microRNAs can promote tumorigenesis and metastasis [15, 16]. Recent studies have demonstrated that microRNAs can act as either potent oncogenes or tumor suppressor genes .
MiR-505 has been identified to function as a tumor suppressor in breast cancer [18–20]. Numerous studies have indicated that miR-505 inhibits cell proliferation by inducing apoptosis and can promote chemoresistance in breast cancer [18, 21]. Expression of miR-505 correlates with established prognostic biomarkers in breast cancer . Moreover, data from mouse models has indicated an association between miR-505 and human basal-type breast cancer . Another study recently provided evidence that miR-505 could suppress the epithelial-mesenchymal transition (EMT) and metastasis in nasopharyngeal carcinoma . However, little is known about the biological function and target genes of miR-505 in EC.
Transforming growth factor-α (TGF-α) is a member of the epidermal growth factor family of mitogens and is encoded by the TGFA gene. TGF-α binds to the epidermal growth factor receptor (EGFR) to initiate a series of biological processes including cell proliferation, differentiation and development . TGF-α makes an important contribution to cell proliferation and invasion in triple-negative breast cancer , and strongly correlates with metastasis in advanced prostate cancer . Besides, TGF-α is also involved in EC tumorigenesis and reported to promote angiogenesis in endothelial cells [27, 28]. Zhu et al. reported that miR-152 could potentially controls migration and invasion by targeting TGF-α in prostate cancer cell lines ; Jin et al. reported that miR-376c could inhibit cell proliferation and invasion by targeting TGF-α in osteosarcoma ; Qin et al. reported that miR-124 may regulates TGF-α-induced EMT in human prostate cancer cells . These studies suggest us that TGF-a may have potential as a target in inhibiting endometrial cancer tumorigenesis and progression through down-regulating by relative microRNA. We analyzed the mRNA sequence of TGF-α and identified binding sites for miR-505 in TGFA.
Here, we report that miR-505 functions as a tumor suppressor in EC by targeting and regulating TGFA.
Associations between miR-505 expression and the clinicopathological features of EC
Overexpression of miR-505 inhibits proliferation, induces apoptosis and reduces the tumorigenicity of EC cells in vitro
miR-505 directly targets TGFA and regulates TGF-α expression in EC cells
Overexpression of miR-505 inhibits the growth of EC xenografts in a mouse model
This study demonstrates that miR-505 is significantly downregulated in human EC compared to normal endometrial tissues, and the expression of miR-505 was significantly associated with the FIGO stage and lymph node metastasis. Additionally, overexpression of miR-505 significantly inhibited EC cell proliferation, induced G1-S arrest and apoptosis, and suppressed EC cell invasion and migration in vitro. Taken together, this data indicates that downregulation of miR-505 could promote the development and progression of EC.
The growth factor TGF-α is mainly secreted during embryogenesis and is frequently overexpressed in malignant tumors, including osteosarcoma, hepatic cancer, prostate cancer and breast cancer [20, 22, 26, 32, 33]. Recent studies have linked TGF-α overexpression to the invasive ability of triple-negative breast cancer cells . Interestingly, overexpression of TGF-α could interact with mesenchymal-to-epithelial transition (MET) and contribute to cetuximab resistance in patients with colorectal cancer [35, 36]. High TGF-α expression was prognostic for poor overall survival in high-risk patients with melanoma . In this study, target prediction software identified a miR-505 binding site in the 3′ UTR of TGFA, and dual-luciferase reporter assays confirmed that TGFA is a direct target of miR-505. In confirmation of this functional interaction, overexpression of miR-505 reduced both TGF-α mRNA and protein expression in EC cell lines.
TGF-α binds to the epidermal growth factor receptor (EGFR) to initiate multiple cellular events, including cell proliferation, and this process has been associated with tumorigenesis and angiogenesis [38, 39]. We infer that upregulation of miR-505 may inhibit proliferation, migration and invasion; promote apoptosis in EC by leading to decreased expression of TGF-α. MMP2 and MMP9 are two of the most studied members of the matrix metalloproteinase (MMPs) family, and play central roles in cell invasion and metastasis by cleaving components of the extracellular matrix (ECM) . In this study, overexpression of miR-505 downregulated both MMP2 and MMP9 mRNA and protein expression, providing further evidence that upregulation of miR-505 may inhibit invasion and metastasis in EC.
During late G1 phase, the CDK2/cyclin E complexes regulate the G1 to S phase transition and the CDK2/cyclin A complexes play an important role in S phase progression [40, 41]. Bcl-2 associated X protein (Bax) is a representative member of Bcl-2 family that promotes apoptosis via the caspase-dependent pathway and is frequently downregulated in cancer . Poly ADP-ribose polymerase (PARP) participates in DNA repair and can inhibit apoptosis [43–45]. In this study, overexpression of miR-505 reduced CDK2 mRNA and protein expression, upregulated Bax and increased the levels of cleaved PARP. Therefore, these results indicate that upregulation of miR-505 promotes apoptosis in EC by upregulating Bax and PARP and inducing G1-S stage arrest via downregulation CDK2.
A mouse model of EC was established to further investigate the function of miR-505 in EC in vivo. Overexpression of miR-505 significantly inhibited tumor xenograft growth and led to a reduced tumor volume. IHC staining confirmed that the tumors formed by miR-505-transfected cells expressed lower levels of TGF-α. These results provide further confirmation that miR-505 might act as tumor suppressor in EC by targeting TGFA.
In conclusion, we demonstrate that miR-505 suppresses cell proliferation, invasion and metastasis in EC by targeting TGFA. This knowledge may provide the basis for further investigations to identify novel diagnostic and therapeutic methods for EC.
Tissue specimen collection
67 Endometrial adenocarcinomas (ECs) and 20 normal endometrial specimens were collected from patients who underwent surgical resection at the Gynecology Department, First Affiliated Hospital of China Medical University (Shenyang, Liaoning Province, China) between May 2013 and May 2015. No patients had received any treatment before surgery. Tumor staging and pathology were based on the FIGO criteria (2009). The China Medical University ethic committee approved this research project and informed consent was obtained from each patient. Tissues were immediately frozen in liquid nitrogen and stored at −80 °C until analysis.
Cell culture and transfection
The human endometrial cancer cell lines HEC-1B (poorly differentiated, estrogen receptor-negative endometrial adenocarcinoma) and Ishikawa (highly differentiated, estrogen receptor-positive endometrial adenocarcinoma) were obtained from the ATCC (Manassas, VA, USA) and maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10 % fetal bovine serum and 1 % penicillin and streptomycin at 37 °C in a humidified atmosphere containing 5 % CO2. Cells were each transfected with miR-505 mimic using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, USA) according to the manufacturer’s protocol. The miR-505 mimic sequence was GGG AGC CAG GAA GUA UUG AUG U, and the scrambled mimic (Mock) sequence was ACU ACU GAG UGA CAG UAG A. The scrambled mimic was also transfected in cells as negative control.
Cell proliferation assay
Cell proliferation was monitored using CCK-8 reagent (Dojindo, Tokyo, Japan) following the manufacturer’s protocol. EC cells were transfected with miR-505 mimic or scrambled mimic, seeded into 96-well plates (2 × 103 cells per well) and incubated until adherent. Cell proliferation was assessed every 24 h (up to 72 h); 10 μL CCK-8 solution was added to the medium in each well, incubated for 4 h and the absorbance values were measured at 450 nm using a microplate reader.
Cell cycle analysis
Cells were trypsinized, harvested, washed twice with PBS, fixed with 70 % ice-cold ethanol in −20 °C overnight, washed with PBS, and then incubated with RNAase and stained with PI (BD Biosciences, New Jersey, USA) following the manufacturer’s protocol. The PI signal was examined by a flow cytometry; a total of 10,000 cells were assessed for each sample.
Apoptosis was quantified using 7AAD and PE-labeled Annexin V (BD Biosciences) following the manufacturer’s protocol and flow cytometry. Cells were collected 48 h after transfection, washed twice with cold PBS, and resuspended at 1 × 106 cells/mL and mixed with 100 μL of 1× buffer and 5 μL Annexin V- PE and 7AAD, incubated for 15 min in the dark, 400 μL 1× buffer was added, and the cells were subjected to cytometry flow within 1 h.
Wound healing assay
Cells were seeded into 6-well plates, allowed to adhere and transfected with miR-505 mimic or scrambled mimic, linear wounds were created in the confluent monolayers using a pipette tip. Cells were washed three times with PBS, the medium was changed to FBS-free DMEM, and photos were captured using a light microscope at 0 h, 24 h and 48 h. The wound healing rate = (Area of original wound − Area of actual wound at different times)/Area of original wound × 100 %.
In vitro cell invasion assay
Cells transfected with miR-505 mimic or mock mimic were collected after 48 h, re-suspended in serum-free DMEM medium, and 5 × 104 cells in serum-free medium were seeded into the upper chamber of Transwell inserts that had been pre-coated with Matrigel (40 μL of 8 mg/mL stock solution; Becton-Dickinson Labware, Bedford, MA, USA); normal culture medium was placed into the lower chamber. Cells were allowed to migrate for 48 h at 37 °C, then the membranes were fixed with methanol and stained with 0.1 % crystal violent. Cell invasion was measured by counting the number of cells attached to the lower side of the membrane in ten high-powered (200×) fields under a light microscope.
Total RNA was isolated from the treated cells and human tissues using TRIzol reagent (Takara, Shiga, Japan) according to the manufacturer’s instructions, after which OD260/280/320 was measured by spectrophotometer (Unico, Shanghai, China). The value of OD260/280 within 1.8–2.0 means high RNA quality, and the sample concentration = sample dilution factor * (OD260-OD320) * 0.04. 2 μg was reverse-transcribed to complementary DNA (cDNA) using avian myeloblastosis virus transcriptase and random primers (Takara). Real-time RT-PCR analysis was performed in triplicate on the ABI prism 7000 sequence detection system (Applied Biosystems) using the SYBR Green PCR Master Mix (Applied Biosystems, Eugene, OR, USA). The relative expression of target genes was determined by comparing the threshold cycle (Ct) of the target genes to the Ct of 18S rRNA (18 s) using the 2-ΔΔCT method . Hairpin-it™ microRNA and U6 snRNA Normalization RT-PCR Quantitation (GenePharma) was used to check mature miR-505 in cells.
Cells and tissues were lysed in ice-cold RIPA lysis buffer and the concentrations were measured using the protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Protein samples (60 μg) were separated by SDS-PAGE on 10 % gels and transferred onto Hybond membranes (Amersham, Munich, Germany). After blocking with 5 % fat-free milk for 1 h, the membranes were incubated with primary antibodies against MMP2, MMP9, Cyclin A1, CDK2, Bax, PARP, TGF-α (1:500, Proteintech, Proteintech Group, USA) and GAPDH (1:2000, Proteintech, Proteintech Group, USA) overnight in 4 °C, then incubated with anti-mouse, anti-rabbit or anti-goat IgG secondary antibodies (1:5000; Dako, Carpinteria, CA, USA) for 1 h. The bands were developed using ECL Plus detection reagent (Santa Cruz Biotechnology) and visualized on X-ray film (Fujifilm, Tokyo, Japan) using Image Quant LAS 4000 (Fujifilm). Band densities were determined and expressed relative to the internal control GAPDH.
Dual-luciferase reporter assay
Luciferase assays were carried out to confirm the interaction between miR-505 and the 3′ untranslated region (UTR) of TGFA. HEK293T cells were seeded into 24-well plates, cotransfected with 50 nM miR-505 or scrambled mimic and 600 ng of dual luciferase vector expressing the wild-type or mutant 3′-UTR TGF-α sequences. After 24 h, the luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) according to the manufacturer’s protocol. The ratio of firefly to renilla luciferase signal was used to normalize firefly activity for intra-experimental transfection efficiency.
In vivo tumorigenesis model
An in vivo model of EC was established by subcutaneously injecting 5-week-old female BALB/c nude mice with 1 × 107 HEC-1B cells transfected with miR-505 (or mock transfected) suspended in PBS (10 mice per group). The weight of the mice and tumor volumes were determined every 3 days; tumor volume was assessed by measuring the length (L) and width (W) using calipers (tumor volume, mm3 = 0.5 × L× W2. After 8 weeks, the mice were euthanized and the tumors were excised, measured and photographed. All mice were obtained from Shanghai SLAC Laboratory Animal, Co., Ltd. (Shanghai, China) and housed in a specific pathogen-free environment. This experiment was in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by China Medical University Animal Care and Use Committee.
Consecutive tissue sections of the xenograft tumors were subjected to IHC to detect TGF-α expression. After deparaffinization, dehydration and boiling to unmask antigens, sections were blocked and incubated with TGF-α antibodies overnight at 4 °C, then incubated with HRP-conjugated anti-rabbit antibodies (Dako) for 15 min.
Data are presented as mean ± SD and were analyzed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). The unpaired two-tailed Student’s t-test, Mann–Whitney U-test and Spearman’s correlation test were used to compare the two groups. All P-values are two-sided; P < 0.05 represents statistical significance.
This work was supported by the Natural Scientific Foundation of China (Nos. 81202049; 81472440; 81472502) and Liaoning Science and Technology Grant (L2013021077).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.View ArticlePubMedGoogle Scholar
- Deligdich L, Holika CF. Endometrial carcinoma: two diseases? Cancer Detect Prev. 1987;10(3–4):237–46.Google Scholar
- Deligdisch L. When cancer of the endometrium is not a good cancer. Rev Fr Gynecol Obstet. 1990;85(10):513–6.PubMedGoogle Scholar
- Kreizman-Shefer H, Pricop J, Goldman S, Elmalah I, Shalev E. Distribution of estrogen and progesterone receptors isoforms in endometrial cancer. Diagn Pathol. 2014;9:77.PubMed CentralView ArticlePubMedGoogle Scholar
- Ray M, Fleming G. Management of advanced-stage and recurrent endometrial cancer. Semin Oncol. 2009;36(2):145–54.View ArticlePubMedGoogle Scholar
- Lotocki RJ, Copeland LJ, DePetrillo AD, Muirhead W. Stage I endometrial adenocarcinoma: treatment results in 835 patients. Am J Obstet Gynecol. 1983;146:141–5.View ArticlePubMedGoogle Scholar
- Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, et al. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 2008;110(2):206–15.View ArticlePubMedGoogle Scholar
- Yoon A, Park JY, Park JY, Lee YY, Kim TJ, Choi CH, et al. Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases. Gynecol Oncol. 2014;132(1):70–5.View ArticlePubMedGoogle Scholar
- Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482(7385):347–55.PubMed CentralView ArticlePubMedGoogle Scholar
- Olivieri F, Rippo MR, Monsurrò V, Salvioli S, Capri M, Procopio AD, et al. MicroRNAs linking inflamm-aging, cellular senescence and cancer. Ageing Res Rev. 2013;12(4):1056–68.View ArticlePubMedGoogle Scholar
- Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122(1):6–7.View ArticlePubMedGoogle Scholar
- Bray F, Loos AH, Oostindier M, Weiderpass E. Geographic and temporal variations in cancer of the corpus uteri: incidence and mortality in pre- and postmenopausal women in Europe. Int J Cancer. 2005;117:123–31.View ArticlePubMedGoogle Scholar
- Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495–500.View ArticlePubMedGoogle Scholar
- Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115:787–98.View ArticlePubMedGoogle Scholar
- Yan J, Gumireddy K, Li A, Huang Q. Regulation of Mesenchymal Phenotype by MicroRNAs in Cancer. Curr Cancer Drug Targets. 2013;13(9):930–4.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhong X, Coukos G, Zhang L. miRNAs in human cancer. Methods Mol Biol. 2012;822:295–306.PubMed CentralView ArticlePubMedGoogle Scholar
- Vasudevan S, Tong Y, Steitz JA. Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation. Science. 2007;318(5858):1931–4.View ArticlePubMedGoogle Scholar
- Yamamoto Y, Yoshioka Y, Minoura K, Takahashi RU, Takeshita F, Taya T, et al. An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer. 2011;10:135.PubMed CentralView ArticlePubMedGoogle Scholar
- Verduci L, Simili M, Rizzo M, Mercatanti A, Evangelista M, Mariani L, et al. MicroRNA (miRNA)-mediated interaction between leukemia/lymphoma-related factor (LRF) and alternative splicing factor/splicing factor 2 (ASF/SF2) affects mouse embryonic fibroblast senescence and apoptosis. J Biol Chem. 2010;285:39551–63.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhu M, Yi M, Kim CH, Deng C, Li Y, Medina D, et al. Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage. Genome Biol. 2011;12(8):R77.PubMed CentralView ArticlePubMedGoogle Scholar
- Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.View ArticlePubMedGoogle Scholar
- Qin Z, He W, Tang J, Ye Q, Dang W, Lu Y, et al. MicroRNAs Provide Feedback Regulation of Epithelial-Mesenchymal Transition Induced by Growth Factors. J Cell Physiol. 2015; May 29.Google Scholar
- Jonsdottir K, Janssen SR, Da Rosa FC, Gudlaugsson E, Skaland I, Baak JP, et al. Validation of Expression Patterns for Nine miRNAs in 204 Lymph-Node Negative Breast Cancers. PLoS One. 2012;7(11), e48692.PubMed CentralView ArticlePubMedGoogle Scholar
- Badawy AA, El-Hindawi A, Hammam O, Moussa M, Gabal S, Said N. Impact of epidermal growth factor receptor and transforming growth factor-α on hepatitis C virus-induced hepatocarcinogenesis. APMIS. 2015;123(10):823–31.View ArticlePubMedGoogle Scholar
- Giricz O, Calvo V, Peterson EA. TACE-dependent TGF-alpha shedding drives triple-negative breast cancer cell invasion. Int J Cancer. 2013;133(11):2587–95.PubMed CentralPubMedGoogle Scholar
- DeHaan AM, Wolters NM, Keller ET and Ignatoski KM. EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate. 2009; 69:528–37.PubMed CentralView ArticlePubMedGoogle Scholar
- Ferrer I, Alcántara S, Ballabriga J, Olivé M, Blanco R, Rivera R, et al. Transforming growth factor-α (TGF-α) and epidermal growth factor-receptor (EGF-R) immunoreactivity in normal and pathologic brain. Prog Neurobiol. 1996;49(2):99–123.View ArticlePubMedGoogle Scholar
- Schreiber AB, Winkler ME, Derynck R. Transforming growth factoralpha:a more potent angiogenic mediator than epidermal growth factor. Science. 1986;232:1250–3.View ArticlePubMedGoogle Scholar
- Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao L, et al. miR-152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines. Prostate. 2013;73(10):1082–9.View ArticlePubMedGoogle Scholar
- Jin Y, Peng D, Shen Y, Xu M, Liang Y, Xiao B, et al. MicroRNA-376c inhibits cell proliferation and invasion in osteosarcoma by targeting to transforming growth factor-alpha. DNA Cell Biol. 2013;32(6):302–9.View ArticlePubMedGoogle Scholar
- Qin W, Pan Y, Zheng X, Li D, Bu J, Xu C, et al. MicroRNA-124 regulates TGF-α-induced epithelial-mesenchymal transition in human prostate cancer cells. Int J Oncol. 2014;45(3):1225–31.PubMedGoogle Scholar
- Hou CH, Lin FL, Tong KB, Hou SM, Liu JF. Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway. Biochem Pharmacol. 2014;89(4):453–63.View ArticlePubMedGoogle Scholar
- Kimura M, Moteki H, Ogihara M. Involvement of endogenous transforming growth factor-α in signal transduction pathway for interleukin-1β-induced hepatocyte proliferation. Eur J Pharmacol. 2014;745:223–33.View ArticlePubMedGoogle Scholar
- Mouradian M, Kikawa KD, Johnson ED, Beck KL, Pardini RS. Key roles for GRB2-associated-binding protein 1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin E2 and transforming growth factor alpha in linoleic acid-induced upregulation of lung and breast cancer cell growth. Prostaglandins Leukot Essent Fatty Acids. 2014;90(4):105–15.PubMed CentralView ArticlePubMedGoogle Scholar
- Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, et al. Increased TGF-a as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells. Clin Cancer Res. 2013;19(24):6751–65.View ArticlePubMedGoogle Scholar
- Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol. 2010;28:1181–9.View ArticlePubMedGoogle Scholar
- Shih IM, Herlyn M. Autocrine and paracrine roles for growth factors in melanoma. In Vivo. 1994;8(1):113–23.PubMedGoogle Scholar
- Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, et al. A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med. 2014;12:19.PubMed CentralView ArticlePubMedGoogle Scholar
- McInnes C, Wang J, Al Moustafa AE, Yansouni C, O’Connor-McCourt M, Sykes BD. Structure-based minimization of transforming growth factor-alpha (TGF-alpha) through NMR analysis of the receptor-bound ligand. Design, solution structure, and activity of TGF-alpha 8–50. J Biol Chem. 1998;273(42):27357–63.View ArticlePubMedGoogle Scholar
- Somerville RP, Oblander SA, Apte SS. Matrix metalloproteinases: old dogs with new tricks. Genome Biol. 2003;4(6):216.PubMed CentralView ArticlePubMedGoogle Scholar
- Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004;18:2699–711.View ArticlePubMedGoogle Scholar
- Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006;3(12), e486.PubMed CentralView ArticlePubMedGoogle Scholar
- Volkmann N, Marassi FM, Newmeyer DD, Hanein D. The rheostat in the membrane: BCL-2 family proteins and apoptosis. Cell Death Differ. 2014;21(2):206–15.PubMed CentralView ArticlePubMedGoogle Scholar
- Jeggo PA. DNA repair: PARP - another guardian angel? Curr Biol. 1998;8(2):R49–51.View ArticlePubMedGoogle Scholar
- Donizy P, Halon A, Surowiak P, Pietrzyk G, Kozyra C, Matkowski R. Correlation between PARP-1 immunoreactivity and cytomorphological features of parthanatos, a specific cellular death in breast cancer cells. Eur J Histochem. 2013;57(4), e35.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen S, Jiao JW, Sun KX, Zong ZH, Zhao Y. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Des Devel Ther. 2015;9:5225–35.PubMed CentralPubMedGoogle Scholar